FMC (FMC) says 2027 is expected to mark the start of FMC's earnings inflection

Management language of this kind typically accompanies a down-cycle narrative: near-term numbers remain soft, and the story is pushed forward to when new product launches, volume normalisation in the distribution channel, and the patent-cliff drag on older chemistries flip from headwind to tailwind. The distinction worth drawing is between an inflection driven by new active ingredient launches, which depends on registration timelines and launch execution, and one driven purely by channel restocking, which tends to arrive earlier but fade faster. Companies in this position have historically been judged on whether interim quarterly prints track the promised glide path, since a distant inflection date gives management room but also invites scepticism if interim metrics slip. Worth watching are volume versus price decomposition in upcoming prints, channel inventory commentary, and any shift in the cost programme, which has been a central lever for the group through the downturn. As guidance rather than a print, the statement is directional and its credibility rests on interim delivery.